News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Integra LifeSciences (IART)’s DuraSeal Dural Sealant Saves Healthcare Costs According To A Study Recently Published In The Journal Of Health Economics And Outcomes Research



8/11/2017 9:48:08 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs

PLAINSBORO, N.J., Aug. 11, 2017 (GLOBE NEWSWIRE) -- Integra LifeSciences (NASDAQ:IART), a leading global medical technology company, has announced the publication of a new economic study, “A cost-benefit analysis of using polyethylene glycol hydrogel sealant versus fibrin glue as a dural sealant for posterior fossa surgery in the United States.” The study, published in the Journal of Health Economics and Outcomes Research, demonstrated an average cost savings of $1,666 per patient when using Integra’s DuralSeal® dural sealant versus fibrin glue.

Cerebrospinal fluid (CSF) leaks after posterior fossa surgery are a significant cause of longer hospital stays, hospital readmissions and other costly post-surgical interventions. This study demonstrated that the greater clinical effectiveness of Integra’s DuraSeal dural sealant at preventing CSF leaks compared to fibrin glue after posterior fossa surgery may help hospitals reduce costs.

The study, conducted by Dr. Marissa J. Carter, a renowned health economist, biostatistician, and clinical trial designer, confirmed a positive, consistent, cost-benefit that averaged $1,666 per patient for hospitals and surgeons who choose Integra’s DuraSeal dural sealant instead of fibrin glue. The study included 200 real-world patients in the U.S. who underwent posterior fossa neurosurgery.

The potential savings are based on the proven clinical efficacy of DuraSeal versus fibrin glue to reduce incisional cerebrospinal fluid leaks as found by Than et. al. in their independent clinical study, “Polyethylene glycol hydrogel dural sealant may reduce incisional cerebrospinal fluid leak after posterior fossa surgery,” conducted at the Johns Hopkins University School of Medicine.1

“Integra understands that today’s healthcare providers must deliver the best treatment options to patients in a cost-effective way,” said Ajit Patwardhan, MD, senior medical director, Integra LifeSciences. “Integra’s DuraSeal brand dural sealant is the only dural sealant indicated for dural closure with both clinical and economic evidence. This evidence makes DuraSeal the better clinical choice for surgeons and patients while also meeting the cost considerations of hospital administrators and operating room directors.”

Dr. Carter’s health economics study is published online in the Journal of Health Economics and Outcomes Research, an international publication that covers all fields and methodologies related to health economics and employs a rigorous double blind peer review process. Click here for the full study or visit the Journal of Health Economics and Outcomes Research web site at http://www.jheor.org (registration required).

1Than KD, Baird CJ, Olivi A. Polyethylene glycol hydrogel dural sealant may reduce incisional cerebrospinal fluid leak after posterior fossa surgery. Neurosurgery. 2008;63 (suppl 1):ONS182-ONS1. https://www.ncbi.nlm.nih.gov/pubmed/18728598).

Integra’s DuraSeal dural sealant is a polyethylene glycol hydrogel with U.S. FDA approved formulations for use in both the brain and spine. Since its introduction in 2003, DuraSeal has been used in more than a million patients around the world. DuraSeal is distributed in more than 40 countries.

About Integra

Integra LifeSciences is dedicated to limiting uncertainty for clinicians, so they can concentrate on providing the best patient care. Integra offers innovative solutions, including leading plastic and regenerative technologies, in specialty surgical solutions, orthopedics and tissue technologies. For more information, please visit www.integralife.com.

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the products and services provided by Integra. Such forward looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of surgical professionals to use Integra products may affect the prospects for their use in surgical procedures. In addition, the economic, competitive, governmental, technological and other factors, identified under the heading "Risk Factors" included in Item IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2016 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.

CONTACT: Integra LifeSciences Holdings Corporation Investors Michael Beaulieu 609-750-2827 Michael.beaulieu@integralife.com Media Laurene Isip 609-750-7984 laurene.isip@integralife.com

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES